Damora Therapeutics, Inc. - Common Stock (DMRA)
Price History
Mar 12, 2026 — May 14, 2026Investment Snapshot
- P/B of 2.91 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -7.2%
Damora Therapeutics, Inc. - Common Stock (DMRA) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/B ratio 2.91, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Damora Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, DMRA shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -7.2%.
StockPik's composite Value Score for DMRA is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DMRA shows earnings declining at 879%.